Pharma minds, le podcast de ceux qui font la Pharma
Latest Episode

"Europe's Access Dilemma" (BONUS) - The Innovation Wave? Europe’s Payers Aren’t Convinced

What if Europe’s “innovation wave” isn’t quite what we think it is? In this bonus episode of Pharma minds’ Europe’s Access Dilemma, I speak with Dr. Sabine Vogler, health economist, Head of the Pharmacoeconomics Department at the Austrian National P...

Play Latest Episode

Bienvenue sur Pharma minds !

Je suis Nathalie Lahitte, pharmacienne et exploratrice des grands défis de la pharma et de la santé. J’ai créé Pharma minds pour révéler les voix qui osent bousculer le secteur et imaginer son futur.

Ici, on parle de vraies histoires, de parcours audacieux et d’idées qui changent la donne. Mon but ? Casser les silos, poser les questions qui comptent et inspirer ceux qui feront la différence.

Vous voulez comprendre les enjeux, vous challenger et vous connecter à un écosystème engagé ? Vous êtes au bon endroit !

Reviews

Merci pour ce podcast passionnant

"Des entretiens agréables et instructifs à écouter, un bon rythme et un ton léger pour parler sérieusement tout en mettant à l’aise l’interlocuteur afin qu’il formule bien le fond de sa pensée. Merci …"

bglmn | Nov. 19, 2023

Un Podcast tant attendu !

"Bravo pour ce Podcast qui nous permet d’écouter des grandes voies de la Pharma, comprendre leur parcours, et trouver tout simplement l’inspiration ! Hâte de découvrir la suite !"

Septante 8 | June 1, 2023

Une immersion enrichissante et réussie dans le monde de la pharma

"Pharma Minds est un nouveau podcast a ne pas louper et qui mérite chacune de ses 5 étoiles parce que ça fait du bien un bon podcast en français, dans la bonne humeur et le tout dans un format court. …"

Cboo216 | May 23, 2023

Recent

Oct. 11, 2026

Is the innovation wave real? Europe's payers' view

What if Europe’s “innovation wave” isn’t quite what we think it is? In this bonus episode of Pharma minds’ Europe’s Access Dilemma, I speak with Dr. Sabine Vogler, health economist, Head of the Pharmacoeconomics Department at the Austrian National Public Health Institute (GÖG) and of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies in Vienna. After five episodes looking at Europe’s access dilemma from the perspective of industry, research and consulting, this
Oct. 11, 2026

"Europe's Access Dilemma" (BONUS) - The Innovation Wave? Europe’s Payers Aren’t Convinced

What if Europe’s “innovation wave” isn’t quite what we think it is? In this bonus episode of Pharma minds’ Europe’s Access Dilemma, I speak with Dr. Sabine Vogler, health economist, Head of the Pharmacoeconomics Department at the Austrian National P...
Oct. 11, 2026

😲 Patients are asking for higher drug prices.

Listen to the full episode : https://youtu.be/csI-hdaZ5sg
Oct. 8, 2026

⏳ What does a four-year drug delay really cost Europe?

Listen to the full episode : https://youtu.be/XBsPsktSRaM
Oct. 7, 2026

🏭 His deal: Chinese drugs, made in Europe.

Listen to the full episode  : https://www.youtube.com/watch?v=CvB_onVtOOQ
Oct. 6, 2026

🩺 Standardiser pour mieux personnaliser.

L'épisode complet, réalisé en partenariat avec BD France, sort le 19/10. ✅ Abonnez-vous à Pharma Minds Podcast pour ne pas manquer sa sortie.
Oct. 4, 2026

Cheap medicines, fast access, strong pharma: can Europe have all three?

"The worst of all outcomes is the current default: the level of Europe's contribution to the world will be decided by America." – Graham Cookson, Economist Welcome to the 5th and final episode of "Europe's Access Dilemma", the Pharma Minds mini-series on MFN and access to innovation in Europe. Pay more. Wait longer. Or change the model. Europe wants three things at once: medicines people can afford, fast access to new drugs, and a strong pharma industry. Is that still possible? My guest is G
Oct. 4, 2026

"Europe's Access Dilemma" (5/5) - "Germany has a target on its back" What will Europe give up?

"The worst of all outcomes is the current default: the level of Europe's contribution to the world will be decided by America." – Graham Cookson, Economist Welcome to the 5th episode of Europe's Access Dilemma, the Pharma Minds mini-series on MFN and access to innovation in Europe. Pay more. Wait longer. Or change the model. Europe wants three things at once: medicines people can afford, fast access to new drugs, and a strong pharma industry. Is that still possible? My guest is Graham Cookson